Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Subcutaneous, Topical, Nasal
FDA Designation: Orphan Drug - Keratitis *
Approval Status: Not Approved
Approved Countries: New Zealand | Slovenia | South Africa | Switzerland | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: SIFI SpA
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Nails, Ingrown|Nail Diseases|Surgical Wound Infection
Phase 3: Oral Ulcer|Wounds, Stab|Skin Ulcer|Nose Cancer|Chronic Pain|Liver Cancer|Pressure Ulcer|Wound Infection|Skin Cancer|Communicable Diseases|Surgical Wound Infection|Injuries/wounds Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618000379213p |
WAMohamed | N/A |
Not yet recruiting |
Obesity Hypoventilation Syndrome |
2021-02-26 |
|||
NCT02157415 |
OPM-G-H-1101 | N/A |
Terminated |
Pain Unspecified |
2018-07-01 |
2019-03-20 |
Treatments |
|
NCT01534858 |
OPM-O-H-1102 | N/A |
Completed |
Burns Unspecified |
2015-06-01 |
2019-03-19 |
Treatments |
|
NCT01048307 |
OPM-I-H-0902 | N/A |
Completed |
Varicose Ulcer |
2010-07-01 |
2019-03-19 |
Treatments |
|
2017-000152-26 |
2017-000152-26 | P3 |
Completed |
Surgical Wound Infection |
2022-07-27 |
2022-03-13 |
Treatments |
|
2018-003321-29 |
AntiSeptic | P3 |
Terminated |
Injuries/wounds Unspecified |
2020-07-01 |
2022-03-13 |
Treatments |
|
NCT04055233 |
RECIPE | P3 |
Completed |
Surgical Wound Infection|Communicable Diseases |
2018-09-10 |
2019-08-14 |
Primary Endpoints|Treatments |
|
NCT02394821 |
EE-USP5571275 | P3 |
Completed |
Chronic Pain|Skin Cancer|Liver Cancer|Wound Infection|Pressure Ulcer|Nose Cancer|Wounds, Stab|Oral Ulcer|Skin Ulcer |
2014-07-01 |
2019-03-20 |
Treatments |
|
NCT06338163 |
POSSIBLE | P4 |
Not yet recruiting |
Surgical Wound Infection |
2025-06-30 |
2024-04-05 |
||
NCT01330706 |
ribebeva | P4 |
Completed |
Nail Diseases|Nails, Ingrown |
2011-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/18/2025 |
News Article |
SIFI announces collaboration with the University of California, San Francisco on Acanthamoeba Keratitis |
|
12/16/2024 |
News Article |
SIFI provides updates on the UK and US regulatory pathways for AKANTIOR® in the treatment of acanthamoeba keratitis |
|
08/27/2024 |
News Article |
Avanzanite Bioscience Reports European Commission's Authorisation of Orphan Medicinal Product AKANTIOR® |
|
08/26/2024 |
News Article |
SIFI Receives European Commission Approval for AKANTIOR® |
|
05/02/2024 |
PubMed |
Safety and effectiveness of an antiseptic wound cleansing and irrigation solution containing polyhexamethylene biguanide. |
|
05/02/2024 |
PubMed |
Assessing antibacterial efficacy of a polyhexanide hydrogel versus alginate-based wound dressing in burns. |
|
05/01/2024 |
PubMed |
Novel Effective Medical Therapy for Acanthamoeba Keratitis. |